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Background. The Kidney Disease Outcomes Quality Initia-
tives (K/DOQI) guidelines on bone metabolism and disease in
chronic kidney disease were recently published. Despite lim-
ited evidence of clinical effectiveness and without detailed con-
sideration of cost, these guidelines recommend the use of a
nonmineral-containing phosphate binder (i.e., sevelamer) in
several common clinical situations. The objective of this study
is to use the example of sevelamer to outline the information
that is needed to assist health care payers with the decision to
fund a new and expensive therapy.
Methods. We assessed the clinical benefit of sevelamer by per-
forming a systematic review of all randomized trials evaluating
its use. To estimate the direct budget impact associated with im-
plementation of the K/DOQI bone disease guidelines, we used
laboratory and medication data available from two cohorts of
dialysis patients (one treated in Canada and one in the United
States) to determine the proportion of patients who meet the
criteria for the use of sevelamer as described in the K/DOQI
bone disease guidelines.
Results. No randomized trials document the impact of seve-
lamer on survival, hospitalization, or quality of life. However,
at least 51% and 64% of dialysis patients in the Canadian and
American cohorts, respectively, would meet K/DOQI criteria
for use of sevelamer. Extrapolating to the United States dialy-
sis population, adoption of the K/DOQI bone guidelines would
result in expenditures of approximately $781 million annually
on sevelamer alone.
Conclusion. Given their potential budgetary impact, future
nephrology clinical practice guidelines should consider resource
use, in addition to clinical data.
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Kidney failure has a substantial impact on life ex-
pectancy and health-related quality of life (HRQOL)
[1, 2]. Although dialysis prolongs life for patients with
end-stage renal disease (ESRD), morbidity and mortal-
ity remain high in this population. An increasing body of
retrospective outcomes research demonstrates an associ-
ation between hyperphosphatemia, an elevated calcium-
phosphate product, hypoparathyroidism [defined as a
parathyroid hormone (PTH) level <65 pg/mL] and sur-
vival in ESRD patients [3–8]. The purported link to mor-
tality remains inadequately defined but may be mediated
through a higher risk of cardiovascular disease [9–12] [ab-
stract; Davies M, et al: J Am Soc Nephrol 13:59, 2002].
Attempting to adequately control hyperphosphatemia
remains the cornerstone of managing abnormal mineral
metabolism in ESRD, including dietary phosphate re-
striction, the use of oral phosphate binders, and modifica-
tion of the dialysis prescription. Recent work advocates
the use of sevelamer, a nonmineral-containing phosphate
binder purported to minimize vascular calcifications [13–
16]. It has been suggested that sevelamer may also de-
crease the incidence and severity of endothelial and soft
tissue damage that is associated with the use of excessive
oral calcium salts [14, 17].
Structured clinical practice guidelines (CPGs) have
been introduced to minimize inappropriate practice vari-
ability for the management of mineral metabolism. The
Kidney Disease Outcomes Quality Initiatives (K/DOQI)
CPGs recommend the use of noncalcium nonaluminium
nonmagnesium-containing binders in several common
clinical situations [18]. As with many contemporary
CPGs, the economics of the intervention, especially in the
context of the health care delivery system, were not dis-
cussed in the K/DOQI document [18]. This is an especially
challenging omission when the CPGs are implemented
and monitored through clinical performance measures
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(CPMs) [19], which is a mandatory component of CPG
implementation [19].
If the cost of all phosphate binders were similar, then
the choice of agent might rest only on opinions of compar-
ative efficacy for a patient subgroup. However, sevelamer
is several times more expensive than calcium salts, which
are the preponderant agents used for hyperphosphatemia
in North America. Therefore, information on health out-
comes (defined as clinical benefits) and the resources con-
sumed (defined as costs) by this new therapy is critical
prior to comprehensive reimbursement [20]. However,
since the impact of sevelamer and calcium-based phos-
phate binders on survival and quality of life is not avail-
able, a formal economic evaluation is not feasible. In an
effort to summarize available information on the clinical
benefit and economic impact of sevelamer, we first per-
formed a systematic review of all relevant randomized tri-
als. Next, using data from dialysis cohorts in Canada and
in the United States, we forecast expenditures on seve-
lamer that would result from adoption of the K/DOQI
CPGs on bone metabolism and disease in chronic kidney
disease [18].
METHODS
Clinical effects of sevelamer
In assessing the clinical effects of sevelamer, we only
considered data from randomized trials, because of the
well-known potential for bias associated with observa-
tional studies. To identify all trials which randomized
ESRD patients to sevelamer versus placebo or active
therapy, we searched Medline using the terms “seve-
lamer” or “Renagel” in databases from January 1969
to May 2003. We also searched the Cochrane Library
and the Database of Abstracts and Reviews using “seve-
lamer” or “Renagel.” Last, we examined proceedings
from the American Society of Nephrology meetings be-
tween 2000 and 2002 and reviewed the reference lists of
clinical trials meeting our inclusion criteria for other po-
tentially relevant studies. Any trial that was deemed wor-
thy of manual review was recorded, as well as the reasons
for subsequent exclusion (if applicable). The search was
not restricted to the English language.
Actual and potential costs of sevelamer and
calcium-based phosphate binders
The acquisition costs of sevelamer and calcium-
based phosphate binders per patient treated were de-
termined from the 200l Drug Topics RedBook [21]. We
assumed that sevelamer recipients would receive 6.5 g per
day, and patients treated with calcium-based phosphate
binders would receive 4.3 g per day, which were the mean
doses required by subjects in the longest randomized clin-
ical trial [14]. We estimated the potential budget impact of
sevelamer based on the recent K/DOQI bone guidelines.
To estimate the budget impact associated with each of
the K-DOQI bone disease CPGs, we performed a cross-
sectional analysis using prospectively collected data from
prevalent Canadian and American patients who required
hemodialysis or peritoneal dialysis in June 2002. We de-
termined the proportion of dialysis patients in each pop-
ulation that would meet K/DOQI criteria for the use of
sevelamer. Since patient characteristics and clinical prac-
tice patterns differ between Canadian and American dial-
ysis populations, we performed these analyses separately
for each country.
The Canadian cohort included all hemodialysis and
peritoneal dialysis patients who reside within the Cal-
gary Health Region in Calgary, Alberta, Canada (catch-
ment area = 1.0 million persons). In the Calgary Health
Region, laboratory, medication and clinical information
are captured for all patients with kidney failure using a
computerized database [22]. Routine laboratory data are
monitored on a monthly basis, and medication data are
updated monthly or every 3 months (for hemodialysis
and peritoneal dialysis patients, respectively). The use of
injectable medications is recorded continuously for all
dialysis patients.
The American cohort was comprised of a random sam-
ple of patients from Dialysis Clinic Incorporated (DCI),
a not-for profit dialysis provider with ∼200 dialysis facili-
ties throughout the United States. Laboratory and medi-
cation information are collected monthly on average and
recorded electronically within a central electronic med-
ical record system. Individual dialysis facilities are di-
rected by the local nephrologist(s) but many procedures,
such as the frequency of lab testing are standardized
throughout DCI. Serum albumin, calcium, and phosphate
are collected monthly while intact PTH is collected on av-
erage every 6 months. All laboratory tests are analyzed
at a central laboratory. Data on both oral and injectable
medications are continuously updated. The population
used for this study comprised a random sample drawn
from 11,106 dialysis patients who were active in DCI
on July 1, 2002.
For these analyses, if more than one laboratory test
of interest was measured in a patient during the month
of interest, the first test of the month was recorded. The
absence of phosphate binders on the medication list was
considered to indicate that the patient was not taking
a binder at the time of these analyses. Erring on the
conservative side, if laboratory data were missing, it was
assumed that the patient did not meet the respective crite-
ria for that guideline. Patients who were taking sevelamer
were included in the analysis.
One study compared sevelamer recipients in a random-
ized trial with Medicare beneficiaries (who were not en-
rolled in a clinical trial and did not receive sevelamer) and
found that the former group was less likely to be hos-
pitalized [23]. This benefit was attributed to sevelamer,
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Table 1. Design of available randomized trials studying sevelamer
Author Design Population Treatment arm(s) Control arm Co-intervention Follow-up
Chertow et al [27] Double-blind,
randomized, two
parallel groups
36 HD on stable
dialysis regimens
Sevelamer 1–10
g/day based on
previous dose of
oral Ca
Placebo Vitamin D
metabolites
(unchanged from
prestudy dose)
8 weeks
Bleyer et al [28] Open-label,
randomized,
cross-over
83 HD on stable
doses of Ca or
aluminum-based
Pi binders
Sevelamer 2.8–5.6
g/day adjusted to
serum Pi
2–6 g/day of Ca
acetate adjusted
to serum Pi
CaCO3 to prevent
hypocalcemia
20 weeks
Chertow et al [15] Open-label,
randomized, two
parallel groups
71 HD on stable
dialysis regimens
Sevelamer 2.8–5.6
g/day and 900
mg/day of
elemental Ca
adjusted to serum
Pi
Sevelamer 2.8–5.6
g/day adjusted to
serum Pi
Vitamin D
metabolites
(unchanged from
prestudy dose)
16 weeks
Abstract; Akizawa T
et al, J Am Soc
Nephrol 11:557A,
2000
Open-label,
randomized, four
parallel groups
94 HD with HPi
(6–10 mg/dL)
Sevelamer 1.5 g/day,
3.0 g/day, 6.0
g/day, or 7.5 g/day
— — 11 weeks
Abstract; Kinugasa
E et al, J Am Soc
Nephrol 12:755A,
2001
Open-label,
randomized, two
parallel groups
230 HD with HPi
(>6.0 mg/dL)
Sevelamer 1.3–7.7
g/day adjusted to
serum Pi
CaCO3 1–5 g/day — 11 weeks
Chertow, Burke, and
Raggi [14]
Open-label,
randomized, two
parallel groups
200 HD with HPi
(>5.5 mg/dL)
when all Pi
binders were
withheld
Sevelamer adjusted
to serum Pi and
Ca (mean dose 6.5
g/day)
Ca acetate or
CaCO3 adjusted
to serum Pi and
Ca levels (mean
doses: 4.6 and 3.9
g/day,
respectively)
Dialysate Ca and
dose of vitamin D
metabolites
titrated to serum
Ca, Pi, and PTH
levels
54 weeks
Sadek et al [29] Open-label,
randomized, two
parallel groups
42 HD with PTH
<400 pg/mL with
CaCO3 as only Pi
binder and no
vitamin D
supplementation
Sevelamer 1.2–4.4
g/day adjusted to
serum Pi,
dialysate Ca
and/or dose of
vitamin D
adjusted for
hypocalcemia
CaCO3 at baseline
doses
— 21 weeks
Abbreviations are: HD, hemodialysis; Ca, calcium; CaCO3, calcium carbonate; PTH, parathyroid hormone; Pi, phosphate.
although it is also possible that differences in patient char-
acteristics were responsible. Nonetheless, in the present
study, sensitivity analyses were performed to determine
the magnitude of reduction in hospitalization that would
be required to offset the direct cost of sevelamer [23]. The
cost of inpatient care and baseline hospitalization rates
for patients with kidney disease were obtained from pub-
lished literature [24, 25]. It is possible that lower doses
of sevelamer might be used in routine clinical practice
than in controlled intervention trials, particularly if com-
bination therapy with calcium-based binders is possible
in some patients [26]. Therefore, we also considered the
budgetary impact of using lower doses of sevelamer.
RESULTS
Clinical effects of sevelamer
We identified 81 trials in the search, of which 21 ap-
peared potentially relevant and were retrieved for review.
Five articles fulfilled inclusion criteria (Table 1) [14, 15,
27–29]. We also included two abstracts [abstract; Akizawa
T et al, J Am Soc Nephrol 11:557A, 2000, and abstract;
Kinugasa E et al, J Am Soc Nephrol 12:755A, 2001] that
fit inclusion criteria, but have not been published as full
articles.
Results of the seven randomized trials that were eligi-
ble for inclusion are presented in Table 2. Calcium-based
binders and sevelamer appeared similarly efficacious as
phosphate binders and in controlling the calcium phos-
phate product [14, 15, 29]. Transient hypercalcemia and
suppression of PTH levels were less common with seve-
lamer, although this was not a consistent finding [14, 28].
Sevelamer delayed the progression of vascular calcifica-
tion over a 1-year period in a subgroup of hemodialysis
patients who had evidence of calcification at baseline [14].
In addition, in one study serum bicarbonate levels were
lower in sevelamer recipients, raising concern about the
chronic effects of metabolic acidosis [abstract; Akizawa
T et al, J Am Soc Nephrol 11:557A, 2000].
No studies were identified that examined the impact of
sevelamer on mortality or the incidence of cardiovascu-
lar events in patients with ESRD [17, 30]. Nor was there
direct evidence that sevelamer reduces the incidence of
bone related clinical outcomes, such as bone pain or
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Table 2. Findings of available randomized trials studying sevelamer
Parathyroid Calcium-phosphate
Author Serum calcium Serum phosphate hormone product Serum HCO3 Other clinical effects
Chertow et al
[27]
NSD compared
with placebo (0
vs. −0.2 mg/dL,
P = NS)
↓ compared with
placebo (−1.2
vs. +0.2 mg/dL,
P < 0.04)
— — NSD compared
with placebo
(−0.3 vs. −0.7
mEq/L, P = NS)
↓ in TC and LDL
compared with
placebo
Bleyer et al
[28]
Smaller ↑
compared with
Ca acetate (+0.2
vs. +0.6 mg/dL,
P < 0.0001)
NSD compared
with Ca acetate
(−2.0 vs. −2.1
mg/dL, P =
0.71)
NSD compared with
Ca acetate (−48
vs. −101 pg/mL, P
= 0.17)
NSD compared with
Ca (−17 vs. −16
mg2/dL2, P =
0.66)
— ↓ in hypercalcemia
(≥11 mg/dL)
compared with Ca
acetate (5% vs.
22%, P < 0.0001); ↓
in serum TC, TG,
and LDL compared
with Ca acetate
Chertow et al
[15]
NSD compared
with sevelamer
and CaCO3
group (0 vs.
+0.3 mg/dL, P
= 0.09)
NSD compared
with sevelamer
and CaCO3
group (−2.4 vs.
−2.3 mg/dL, P
= NS)
NSD compared with
sevelamer and
CaCO3 group
(−23 vs. −67
pg/mL, P = 0.07)
NSD compared with
sevelamer and
CaO3 group
(−22.4 vs. –19.6
mg2/dL2, P = NS)
NSD compared
with sevelamer
and CaCO3
(values not
specified)
—
Abstract;
Akizawa T
et al, J Am
Soc
Nephrol
11:557A,
2000
NSD compared
with baseline for
any dose
regimen of
sevelamer
↓ compared with
baseline for all
four dose
regimens of
sevelamer
↓ compared with
baseline for 3, 6,
and 7.5 g/day, but
not 1.5 g/day
doses (−57, −75,
−16, and −23
pg/mL,
respectively)
— — —
Abstract;
Kinugasa
E, et al, J
Am Soc
Nephrol
12:755A,
2001
Smaller ↑
compared with
CaC03 (+0.05
vs. +0.59 mg/dL,
P < 0.0001)
NSD compared
with
CaCO3(−2.3 vs.
−2.3 mg/dL, P
= 0.77)
NSD compared with
CaCO3 (−57 vs.
−124 pg/mL, P =
0.61)
— — ↓ in hypercalcemia
(>11 mg/dL)
compared with
CaCO3 (0% vs.
16.5%, P < 0.0001)
Chertow,
Burke, and
Raggi [14]
Smaller ↑
compared with
oral Ca (+0.1 vs.
+0.4 mg/dL, P
= 0.002)
NSD compared
with oral Ca
(−2.5 vs. −2.3
mg/dL, P =
0.33)
NSD compared with
oral Ca (−8 vs.
−62 pg/mL, P =
0.11)
NSD compared with
oral Ca (−23 vs.
−20 mg2/dL2, P =
0.12)
↓ compared with
oral Ca (19.2 vs.
22.1 mEq/L, P <
0.0001)
↓ in TCl and LDL,
compared with oral
Ca; significantly
slower progression
of coronary artery
and aortic
calcification
compared with oral
Ca
Sadek et al
[29]
NSD compared
with CaCO3
(−0.05 vs. 0
mg/dL, P = NS)
NSD compared
with CaCO3
(+0.03 vs. −0.07
mg/dL, P = NS)
NSD compared with
CaCO3 (+53 vs.
+54 pg/mL, P =
NS)
NSD compared with
CaCO3 (+0.05 vs.
−0.2 mg2/dL2, P
= NS)
NSD compared
with CaCO3
(−0.7 vs. −0.3
mEq/L P = NS)
↓ LDL cholesterol,
compared with
CaCO3
Abbreviations are: NSD, no significant difference; NS, nonsignificant (P > 0.05); Ca, calcium carbonate; TC, total cholesterol; TG, triglycerides; LDL, low-density-
lipoprotein cholesterol.; NR, not reported. Unless otherwise specified, P values refer to effect of sevelamer compared with effect of control group on parameter of
interest.
No study reported significant differences in clinical cardiovascular outcomes, health-related quality of life (HRQOL), mortality, or hospitalization rates.
fracture rate. The impact of sevelamer on (HRQOL) has
not been tested.
Potential budget impact of sevelamer
Based on an average dose of 6.5 g per day, the aver-
age annual cost of sevelamer was $3644 [United States
(U.S.)] per patient per year. In comparison, the costs of
calcium acetate and of calcium carbonate were $463 U.S.
per patient per year and $154 U.S. per patient per year,
respectively, assuming an average dose of 4.3 g per day
of elemental calcium.
We identified 407 hemodialysis and 92 peritoneal dial-
ysis patients in the Calgary Health Region (Canadian
dialysis cohort). The cohort’s demographic characteris-
tics were representative of Canadian dialysis patients [31]
(data not shown). Laboratory data on serum calcium, al-
bumin, and phosphate was available for 473 (95%) pa-
tients while data on intact PTH was available for 388
(78%) patients.
As of September 2002, 60% of patients were using
a calcium-based phosphate binder, 1.0% of dialysis pa-
tients were using sevelamer, and 28% of dialysis pa-
tients were receiving oral or intravenous active vitamin
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Table 3. Kidney Disease Outcomes Quality Initiatives (K-DOQI) Guidelines recommending the potential use of sevelamer among patients with
end-stage renal disease (ESRD) [18]
Guideline
number Summary of guideline recommendation Response for analytic model
5 In dialysis patients, if phosphate >5.5 mg/dL despite oral
calcium, use a combination of oral calcium and sevelamer
Determine the number of dialysis patients treated with calcium
binders with phosphate >5.5 mg/dL
5 In dialysis patients, the total oral calcium dose should be
≤1.5 g/day
Determine the number of dialysis patients whose total CaCO3 dose is
>1.5 g/day
5 and 6 In dialysis patients, calcium-based binders should not be
used in patients with (a) total serum calcium >10.2 mg/dL
or (b) intact parathyroid hormone <150 pg/mL on two
consecutive measurements
Determine the number of dialysis patients who are not on active
vitamin D, but are on calcium-based binders and who have either
(a) total serum calcium >10.2 mg/dL or (b) intact parathyroid
hormone <150 pg/mL on two consecutive measurements
6 Keep predialysis serum calcium-phosphate product <55
mg2/mL2 by reducing phosphate level
Determine the number of patients whose predialysis serum calcium
phosphate product is >55 mg2/mL2
13C If intact parathyroid hormone <100 pg/mL, reduce dose of
calcium-based binders (and switch to sevelamer) and
vitamin D
Determine the number of dialysis patients who are on calcium
binders, but not active vitamin D, and whose parathyroid hormone
level is <100 pg/mL
Table 4. The potential impact of Kidney Disease Outcomes Quality Initiatives (K/DOQI) guidelines on use of sevelamer based on a Canadian
dialysis cohort
Potential cost of sevelamer
Number of dialysis Number of hemodialysis Number of peritoneal associated with adherence to
patients who meet patients who meet dialysis patients who each guideline in a hypothetical
Guideline Criteria criteria (N = 499)a criteria (N = 407) meet criteria (N = 92) 500 patient cohort (U.S. dollars)
5 Phosphate >5.5 mg/dL 99 (20%) 87 (21%) 12 (13%) $361,000
5 Calcium dose >1.5 g/day 81 (16%) 76 (19%) 5 (5%)b $295,000
5 and 6 Calcium >10.2 mg/dL
Parathyroid hormone
<150 pg/mL (two
occasions over 6 months)
45 (9%) 38 (9%) 7 (8%) $164,000
87 (17%) 77 (19%) 10 (11%) $317,000
6 Calcium-phosphate
product >55 mg2/mL2
118 (24%) 99 (24%) 19 (21%) $430,000
13C Parathyroid hormone <100
pg/mL (one occasion)
75 (15%) 68 (17%) 7 (8%) $273,000
Any Patients meeting ≥ one 51%, 95% 54%, 95% CI 49–59 38%, 95% CI 28–49 $933,000, 95%
guideline guidelineb CI 47–56 CI 856,000–1,020,000c
aA small proportion of patients did not have laboratory measurements drawn (5% for calcium/phosphorus, 22% for parathyroid hormone) and were assumed not to
meet the criteria for any of the guidelines but were included in the denominator, which provides conservative estimates for sevelamer use.
bP = 0.002 for binomial test of proportions comparing hemodialysis vs. peritoneal dialysis
cNumbers in this column do not sum to $933,000 since patients may meet more than one criteria for use of sevelamer.
D. Thirty-five percent of dialysis patients who were taking
calcium-based phosphate binders had serum phosphorus
levels >5.5 mg/dL, while 21% of dialysis patients not tak-
ing active vitamin D had corrected [32] serum calcium
levels >10.2 mg/dL. Table 4 highlights the number of pa-
tients in whom K/DOQI guidelines directly or indirectly
recommend the use of sevelamer. Based on fulfillment
of K/DOQI guidelines 5, 6, or 13C (Table 3), 256 of 499
(51%) patients would meet criteria for use of sevelamer
(Table 4).
Assuming an annual cost per patient of $3644 (U.S.),
and that all patients meeting criteria for sevelamer re-
ceived it (i.e., 51% of patients), an additional $933,000
(U.S.) would be spent in this Canadian dialysis cohort.
This amount is 5.4% of all health care spending on these
499 patients [24], or $1865 per capita, which is nearly
two thirds of the annual amount spent on all nonerythro-
poietic medications for the entire cohort [$1.42 million
(U.S.)] [24]. Extrapolating to the rest of Canada where
there are 13,922 dialysis patients [31], adherence to the
K/DOQI bone guidelines could result in an expenditure
of $26 million on sevelamer.
We next identified a random sample of 1600 hemodialy-
sis patients and 400 peritoneal dialysis patients from DCI
(United States dialysis cohort). The demographic charac-
teristics of this cohort were representative of American
dialysis patients [33] (data not shown). Laboratory data
on serum calcium, albumin, and phosphate was available
for 1847 (92%) patients while data on intact PTH was
available for 1764 (88%) patients. Table 5 shows the pro-
portion of patients who met the various K/DOQI criteria
for the use of sevelamer. Overall, the proportion of pa-
tients treated in the United States who met criteria for the
use of sevelamer was substantially higher than in Canada
(64% versus 51%, P < 0.001). Although the majority
of guidelines tended to be met more frequently in the
United States patients, more substantial differences were
noted in the proportion with hyperphosphatemia (30%
versus 20%), high calcium-phosphate products (35% ver-
sus 24%) and requiring high doses of oral calcium (29%
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Table 5. The potential impact of Kidney Disease Outcomes Quality Initiatives (K/DOQI) guidelines on use of sevelamer based on an American
dialysis cohort
Potential cost of sevelamer
associated with adherence
Number of dialysis Number of hemodialysis Number of peritoneal to each guideline in
patients who meet patients who meet dialysis patients who a hypothetical 500 patient
Guideline Criteria criteria (N = 2000)a criteria (N = 1600) meet criteria (N = 400) cohort (U.S. dollars)
5 Phosphate >5.5 mg/dL 592 (30%) 491 (31%) 101 (25%) $539,000
5 Calcium dose >1.5 g/day 586 (29%) 489 (31%) 97 (24%) $534,000
5 and 6 Calcium >10.2 mg/dL 87 (4%) 59 (4%) 28 (7%) $79,000
Parathyroid hormone <150
pg/mL (two occasions
over 6 months)
343 (17%) 275 (17%) 68 (17%) $302,000
6 Calcium-phosphate
product >55 mg2/mL2
707 (35%) 568 (36%) 139 (35%) $607,000
13C Parathyroid hormone <100
pg/mL (one occasion)
316 (16%) 256 (16%) 60 (15%) $288,000
Any guideline Patients meeting ≥ one 64%, 95% CI 62–67 66%, 95% CI 63–68 60%, 95% CI 55–64 $1,166,000; 95%
guidelinea CI 1,130,000–1,221,000b
aA small proportion of patients did not have laboratory measurements drawn (8% for calcium/phosphorus, 12% for parathyroid hormone) and were assumed not
to meet the criteria for any of the guidelines but were included in the denominator, which provides conservative estimates for sevelamer use.
bNumbers in this column do not sum to $1,166,000 since patients may meet more than one criteria for use of sevelamer.
versus 16%). Of the American patients, 30% were receiv-
ing sevelamer. There was no difference in the proportion
of patients who met at least one criterion for sevelamer
use between patients who were or were not on sevelamer
(data not shown).
To comply with the K/DOQI guidelines, sevelamer
might be used in 64% of American hemodialysis patients,
which would represent an expenditure that is nearly 20%
of the capitated fee paid to dialysis providers for regular
hemodialysis of patients in the United States. Making the
same assumptions used for the Canadian dialysis popula-
tion, and extrapolating to the entire United States dialy-
sis population of approximately 335,000 patients [33], this
would project to $781 million per year spent on sevelamer
alone.
To offset the additional cost of sevelamer, hospital-
ization costs for ESRD patients [24] treated with seve-
lamer would need to be reduced by 45% for those treated
in Canada, and substantially more in the United States.
To address the possibility that our projections over-
estimated the true prevalence of sevelamer use, we re-
peated analyses using the lower limit of the 95% CI for the
proportion of sevelamer-eligible Canadian patients (i.e.,
47%). Even in this conservative analysis, $856,000 (U.S.)
would be spent on sevelamer locally (4.1% of health care
spending for all local ESRD patients). Finally, if the ac-
tual dose of sevelamer used was 2.8 g/day [26], rather than
the 6.5 g/day used in our baseline analysis, then $402,000
(U.S.) would be spent on sevelamer in the 499 patient
Canadian cohort ($803 per capita).
DISCUSSION
Routinely available oral therapies for managing hyper-
phosphatemia in North American ESRD patients include
calcium-containing phosphate binders, aluminum or
magnesium-containing binders, and sevelamer, with clear
cost differences between the therapies. The K/DOQI
guidelines for the management of bone and mineral
metabolism recommend sevelamer for use in several
common clinical scenarios. Relying on conservative as-
sumptions, and assuming no price discounts are imple-
mented, we project that implementation of the K/DOQI
guidelines [18] might result in an annual expenditure of
up to $781 million for sevelamer in the United States
alone.
Results of our systematic review suggest that sevelamer
may reduce transient hypercalcemia, although its impact
on hyperphosphatemia, PTH, and calcium-phosphate
product, in comparison to the use of calcium-based
binders, appeared similar. While a recent meta-analysis
conducted by the manufacturers of sevelamer concluded
that sevelamer offered superior metabolic control com-
pared with oral calcium [34], this work pooled results
from observational and randomized studies, a technique
which is prone to bias. Although a decrease in the rate
of progression of vascular calcification was observed in
a subgroup of sevelamer recipients in a randomized trial
[14], the clinical significance of this finding is unknown.
No randomized trials document the effect of sevelamer
on survival or quality of life. We did not include obser-
vational studies in our systematic review because of their
well-documented potential for bias.
There are several potential sources of inaccuracy in
our projections for expenditures on sevelamer that might
occur after the widespread dissemination of K/DOQI
guidelines. Our projections are based on a cross-sectional
examination of prevalent dialysis patients. It is pos-
sible that the proportion of patients meeting criteria
for each guideline might vary month to month, thus
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Table 6. Minimum information needed to evaluate the cost-effectiveness of sevelamer therapy
Outcome Parameter
Clinical outcomes Impact of sevelamer on mortality in patients with ESRD
Impact of sevelamer on overall health-related quality of life (i.e., possibly due to a reduction in morbidity resulting from
bone or cardiovascular disease)
Health care costs Cost of sevelamer compared with standard phosphate binders
Other treatment costsa
Cost of induced therapy, such as additional lab tests
Cost savings due to possible (though unproven) reduction in hospitalization due to less cardiovascular events or fractures
Nonhealth care costs Cost (or savings) due to improved return to work rates, or a reduction in time costs associated with the need to receive
health care
aIncludes those unrelated to management of bone disease. For example, it has been suggested that sevelamer might reduce costs related to lipid-lowering therapy.
resulting in overestimation of the number of patients
who would consistently meet criteria for sevelamer use.
Alternatively, it is possible that our projections may
underestimate the true costs. For instance, a portion
of Guideline 5 states that, “Both calcium based phos-
phate binders and other non-calcium and non-aluminum
containing phosphate-binding agents (such as sevelamer
HCl) are effective in lowering serum phosphorus levels
(EVIDENCE) and either may be used as the primary
therapy (OPINION).” Guideline 5 also states that, “Non-
calcium-containing phosphate binders are preferred in
dialysis patients with severe vascular and or other soft-
tissue calcification (OPINION).” Because these guide-
lines offer nonquantitative, clinical thresholds for the use
of sevelamer, it is possible that the proportion of patients
receiving sevelamer in clinical practice will be substan-
tially higher than our estimates.
As is true for any economic model, the financial pro-
jections are heavily influenced by the input assumptions.
Therefore, sensitivity analyses were performed for sev-
eral key components. If the optimal dose of sevelamer is
reduced by >50% from the amount anticipated from the
clinical trials’ experiences, by the use of a combination
of sevelamer and calcium binders, the costs would still
be substantial. Conversely, because patient adherence is
typically lower than outside of clinical trials, and physi-
cian prescribing practices for medications often are not
those recommended in CPGs, it is possible that the doses
prescribed may be higher or lower than the 6.5 g/day used
for the current models.
The actual cost of an effective medication may not ad-
equately reflect its economic impact if that medication
reduces the occurrence of expensive complications [20].
Because sevelamer has been proposed to prevent car-
diovascular complications of ESRD, and cardiovascular
disease is the principal cause of morbidity and mortal-
ity in ESRD patients, the trade-off was examined based
on hospitalizations. At least a 45% reduction in hospital-
izations would be required to offset the increased costs
of sevelamer. We are unaware of any pharmacologic in-
tervention in the ESRD population that has achieved a
comparable morbidity effect in a randomized trial.
Clinicians might object to reserving judgment on the
benefit of sevelamer until data on hard clinical outcomes
are available, on the basis that such delay would need-
lessly deny potential benefit to patients. However, there
are numerous examples of therapies that were supported
by theoretical benefits or results of observational data,
but yet did not confer benefit to patients when tested in
randomized trials. A relevant example for nephrologists
is the normalization of hemoglobin using erythropoietic
substances, which was strongly supported by clinical intu-
ition and observational data. However, a well-conducted
randomized trial ultimately showed that patients who
were randomized to the higher hemoglobin concentra-
tion had higher rates of vascular access morbidity and
nonsignificantly higher mortality [35].
The impact of costs depends on the economic per-
spective. In Canada, the payer for dialysis-related med-
ications differs by province. In one province, all oral
dialysis-related medications are paid for by the Provin-
cial Renal Agency, which negotiates with the provincial
Ministry of Health for a fixed sum per patient annually.
Addition of a costly medication such as sevelamer, there-
fore, decreases the ability to pay for other medications,
including those of proven benefit for reducing mortality
or favorably impacting quality of life. In the United States,
there is no single payer for oral medications. Charges for
all oral phosphate binders are paid by the beneficiary
and/or their employer-based insurance plan, or state-
administered Medicaid programs. Under economically
constrained payment systems, increasing the costs for one
element of care may decrease the ability or desire of the
payer to be at risk for others.
There is proposed national legislation to expand
Medicare benefits by offering a phosphate binder drug
benefit [S1304, Senator John Kerry (D-MA), 2002].
Before embarking on a policy that offers differential re-
imbursement to sevelamer and would substantially in-
crease program costs, we propose that selected clinical
and fiscal outcomes be captured to better define the
benefit of sevelamer (Table 6). A randomized, inter-
vention trial is currently being conducted to determine
the impact of sevelamer on survival and the incidence
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of cardiovascular events in patients with ESRD. Ide-
ally, this study will also prospectively collect economic
information.
Few health care delivery systems can fund all desired
programs. Choices must be made about which health pro-
grams to fund and which ones to forgo. It is the benefits
associated with forgone health care programs or oppor-
tunities that constitute opportunity costs [20]. Decision-
makers might choose to fund sevelamer, but should only
do so if it is felt that no other (currently unfunded) in-
tervention would better impact survival or HRQOL of
patients with kidney disease. Presently, current data do
not permit a judgment as to whether widespread use of
sevelamer represents a wise or poor use of resources.
Based on conservative economic models, we propose
that implementation of the recommendations on phos-
phate binders from the new K/DOQI bone metabolism
and disease clinical practice guidelines may result in a
substantial increment in total annual health expendi-
tures for ESRD in North America. Before widespread
adoption of these CPGs occurs, these economic issues
should be considered. Moreover, because randomized tri-
als evaluating the impact of sevelamer on conventional
clinical outcomes are lacking, decisions to fund this costly
new therapy seem premature. The example of sevelamer
demonstrates the importance of considering the poten-
tial economic cost and feasibility during the creation of
future clinical practice guidelines.
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